Flutemetamol (18F)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Flutemetamol (¹⁸F) (trade name Vizamyl, by GE Healthcare) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer’s disease.^[1]

Mechanism of action

After the substance is given intravenously, it accumulates in beta amyloid plaques in the patient’s brain, which thus become visible via positron emission tomography (PET).^[1]

References

↑ ^1.0 ^1.1 H. Spreitzer (18 August 2014). “Neue Wirkstoffe – Flutemetamol”. Österreichische Apothekerzeitung (in German) (17/2014): 43.

Template:Diagnostic radiopharmaceuticals

Template:Pharma-stub

[Spreitzer-1] 1.0 ^1.1 H. Spreitzer (18 August 2014). “Neue Wirkstoffe – Flutemetamol”. Österreichische Apothekerzeitung (in German) (17/2014): 43.

[1]